RETRACTED ARTICLE: Reduced LINC00467 elevates microRNA-125a-3p to suppress cisplatin resistance in non-small cell lung cancer through inhibiting sirtuin 6 and inactivating the ERK1/2 signaling pathway

Xue, Feng; Yang, Chuan; Yun, Keli; Jiang, Cailing; Cai, Rui; Liang, Ming; Wang, Quan; Bian, Weixin; Zhou, Hang; Liu, Zhipeng; Zhu, Lin

doi:10.1007/s10565-021-09637-6

Cited by 10 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang et al [23] constructed a competing endogenous RNA (ceRNA) network specific to LINC00467 in LUAD to regulate cancer progression. In addition, silencing LINC00467 upregulates miR-125a-3p to decrease cisplatin resistance via inhibiting SIRT6 and inactivating the ERK1/2 signaling pathway [24]. Taken together, these results indicate that LINC00467 acts as an oncogene in lung cancer and could represent a novel biomarker for its diagnosis, treatment, and prognosis.…”

Section: Linc00467 In Carcinomas Lung Cancermentioning

confidence: 75%

“…1 LINC00467 expression in various cancers online sequencing data from the TCGA LUAD cohort and observed a positive correlation between LINC00467 DNA copy number values and LINC00467 mRNA expression. Subsequently, they assessed the independent prognostic value of LINC00467 copy number alterations in terms of tumor metastasis and overall survival which predict poor prognosis in LUAD [23].The high expression of LINC00467 promoted the proliferation, migration, stemness, invasion of lung cancer cells and modulated cell cycle arrest and apoptosis [16,[19][20][21][22]24]. These results suggested that LINC00467 played an oncogenic function and performed an important role in LUAD development.…”

Section: Linc00467 In Carcinomas Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

LINC00467: an oncogenic long noncoding RNA

et al. 2022

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have been found to play essential roles in the cell proliferation, fission and differentiation, involving various processes in humans. Recently, there is more and more interest in exploring the relationship between lncRNAs and tumors. Many latest evidences revealed that LINC00467, an oncogenic lncRNA, is highly expressed in lung cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, breast cancer, glioblastoma, head and neck squamous cell carcinoma, osteosarcoma, and other malignant tumors. Besides, LINC00467 expression was linked with proliferation, migration, invasion and apoptosis via the regulation of target genes and multiple potential pathways. We reviewed the existing data on the expression, downstream targets, molecular mechanisms, functions, relevant signaling pathways, and clinical implications of LINC00467 in various cancers. LINC00467 may serve as a novel biomarker or therapeutic target for the diagnosis and prognosis of various human tumors.

show abstract

Section: Linc00467 In Carcinomas Lung Cancermentioning

confidence: 75%

Section: Linc00467 In Carcinomas Lung Cancermentioning

confidence: 99%

LINC00467: an oncogenic long noncoding RNA

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Similarly, the difference in deletion mutation between the two groups was more pronounced in cell proliferation in the chemorefractory group ( 41 ). Interestingly, it has been indicated by some studies that inactivating the ERK1/2 signaling pathway would suppress cisplatin resistance in non-small cell lung cancer ( 42 ). It deeply supported the correlation of drug resistance and provided a basis for drug research and development.…”

Section: Discussionmentioning

confidence: 99%

Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer

Han

Zhao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The poor survival rate of small cell lung cancer (SCLC) is mainly related to the condition that patients with SCLC often have good responses to first-line chemotherapy initially, but later on, most of these patients relapse rapidly due to resistance to further treatment. In this study, we attempted to analyze whole-exome sequencing data based on the largest sample size to date, to develop a classifier to predict whether a patient will be chemorefractory or chemosensitive and to explicate the risk of recurrence that affects the prognosis of patients. We showed the different characteristics of somatic mutational signatures, somatic mutation genes, and distinct genome instability between chemorefractory and chemosensitive SCLC patients. Amplified mutations in the chemosensitive group inhibited the regulation of the cell cycle process, transcription factor binding, and B-cell differentiation. Analysis of deletion mutation also suggested that detection of the chromosomal-level variation might influence our treatment decisions. Higher PD-L1 expressions (based on TPS methods) were mostly present among chemosensitive patients (p = 0.026), while there were no differences in PD-L1 expressions (based on CPS methods) and CD8+ TILs between the two groups. According to the model determined by logistic regression, each sample was endowed with a predictive probability value (PV). The samples were divided into a high-risk group (>0.55) and a low-risk group (≤0.55), and the survival analysis showed obvious differences between the two groups. This study provides a reference basis to translate this knowledge into practice, such as formulating personalized treatment plans, which may benefit Chinese patients with SCLC.

show abstract

“…For instance, LINC00467 was highly expressed in gastric cancer and drove the malignant progression of gastric cancer through the miR-27b-3p/STAT3 axis [ 45 ]. LINC00467 was overexpressed in NSCLC, and knockdown of LINC00467 upregulated miR-125a-3p to decrease cisplatin (DDP) resistance in NSCLC cells via inhibiting SIRT6 and inactivating the ERK1/2 signaling pathway [ 46 ]. Furthermore, it was observed that LINC00467 is highly expressed in bladder cancer and can promote bladder cancer progression by regulating the NF-κB signaling pathway [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

Long intergenic non-protein-coding RNA 467 promotes tumor progression and angiogenesis via the microRNA-128-3p/vascular endothelial growth factor C axis in colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are important regulators and biomarkers of tumorigenesis and tumor metastasis. Long intergenic non-protein-coding RNA 467 (LINC00467) is associated with various cancers. However, the role and mechanism of LINC00467 in colorectal cancer (CRC) promotion are poorly understood. This study aimed to present new details of LINC00467 in the progression of CRC. Reverse transcription–polymerase chain reaction demonstrated that the expression level of LINC00467 in CRC tissues and cell lines was significantly upregulated, which was closely related to the clinical features of CRC. Cell and animal studies showed that the downregulation of LINC00467 expression in CRC cells significantly inhibited cell proliferation, metastasis, and angiogenesis. Moreover, the overexpression of LINC00467 accelerated CRC promotion. Bioinformatics analysis and luciferase reporter assay confirmed that LINC00467 binds to miR-128-3p. Rescue experiments manifested that decreased miR-128-3p level reversed CRC cell inhibition by silencing LINC00467. Furthermore, vascular endothelial growth factor C (VEGFC) was identified as a target of miR-128-3p that could reverse the inhibition of cell growth that is mediated by miR-128-3p. Altogether, our results showed that LINC00467 contributes to CRC progression and angiogenesis via the miR-128-3p/VEGFC axis. Our findings expand the understanding of the mechanisms underlying CRC and suggest potential targets for clinical strategies against CRC.

show abstract

RETRACTED ARTICLE: Reduced LINC00467 elevates microRNA-125a-3p to suppress cisplatin resistance in non-small cell lung cancer through inhibiting sirtuin 6 and inactivating the ERK1/2 signaling pathway

Cited by 10 publications

References 38 publications

LINC00467: an oncogenic long noncoding RNA

LINC00467: an oncogenic long noncoding RNA

Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer

Long intergenic non-protein-coding RNA 467 promotes tumor progression and angiogenesis via the microRNA-128-3p/vascular endothelial growth factor C axis in colorectal cancer

Contact Info

Product

Resources

About